Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P48163

UPID:
MAOX_HUMAN

ALTERNATIVE NAMES:
Malic enzyme 1

ALTERNATIVE UPACC:
P48163; B4DZ70; Q16797; Q16855; Q53F72; Q5VWA2; Q9BWX8; Q9H1W3; Q9UIY4

BACKGROUND:
NADP-dependent malic enzyme, known alternatively as Malic enzyme 1, is integral to the metabolic pathways, facilitating the conversion of malate to pyruvate. This enzyme's activity is indispensable for the proper functioning of the citric acid cycle, a key energy-producing pathway. It requires NADP(+) and divalent metal ions to catalyze the decarboxylation of oxaloacetate, highlighting its role in cellular bioenergetics.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of NADP-dependent malic enzyme unveils potential avenues for therapeutic intervention. Given its essential role in metabolism, targeting this enzyme could lead to novel treatments for diseases linked to metabolic dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.